Menu Close

ASCO 2019 Poster Presentation shows improved overall survival for advanced pancreatic cancer patients enrolled in the Know Your Tumor program.

Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.